注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Bioxel Therapeutics Inc是一家商业化阶段的生物制药公司,利用人工智能方法开发神经科学和免疫肿瘤学领域的转化药物。该公司的商业产品IGALMI(开发为BXCL501)是右旋美托咪定的专有舌下薄膜制剂,用于急性治疗成人精神分裂症或双相I或II障碍相关的躁动。BXCL501还被开发用于急性治疗阿尔茨海默病相关的躁动,并作为重度抑郁症的辅助治疗。通过其子公司OnkosXcel Therapeutics,该公司开发了BXCL502作为痴呆症慢性躁动的潜在疗法,BXCL701是一种研究性口服先天性免疫激活剂,用于治疗侵袭性前列腺癌和晚期实体瘤,这些肿瘤的治疗方案尚不成熟。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Vimal D. Mehta | 60 | 2017 | Founder, CEO, President, & Director |
Peter R. Mueller | 66 | 2017 | Independent Chairman & Lead Director |
Alan Breier | - | 2018 | Member of Clinical Advisory Board |
Maurizio Fava | - | 2019 | Member of Clinical Advisory Board |
Steven M. Paul | 72 | - | Member of Advisory Board |
John H. Krystal | - | 2019 | Member of Clinical Advisory Board |
Stephen R. Marder | - | 2018 | Member of Clinical Advisory Board |
George T. Grossberg | - | 2018 | Member of Clinical Advisory Board |
June Bray | 69 | 2021 | Independent Director |
Thomas P. Laughren | - | 2019 | Member of Clinical Advisory Board |
Michal Votruba | 58 | 2019 | Independent Director |
Sandeep Laumas | 54 | - | Director |
Sheila K. Gujrathi | 53 | - | Member of Advisory Board |
Sheldon H. Preskorn | - | 2018 | Member of Clinical Advisory Board |
Thomas R. Kosten | - | 2019 | Member of Clinical Advisory Board |
Michael P. Miller | 66 | 2022 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核